Brand Name(s):Tecentriq

Indication:Urothelial carcinoma (locally advanced or metastatic )
Lung cancer- metastatic non-squamous non-small cell lung cancer (NSCLC). should be used in combination therapy (bevacizumab, paclitaxel and carboplatin)



Review Date:May-26

Safety alert
Manufacturers warn that SCARs, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Patients should be monitored for severe skin reactions. In case a SCAR is suspected, treatment should be withheld and patients should be referred to a specialist.
April 2021

NICE TA638 states Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if they have an ECOG performance status of 0 or 1, and the company provides atezolizumab according to the commercial arrangement.